Drug-eluting metallic stents in urology

Indian Journal of Urology

Volumn 30, Issue 1, 2014, Pages 8-12

  Kallidonis, Panagiotis S ^a   Georgiopoulos, Ioannis S ^a   Kyriazis, Iason D ^a   Al Aown, Abdulrahman M ^a   Liatsikos, Evangelos N ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Drug eluting; metal stent; optical coherence tomography; paclitaxel; sirolimus; ureteral stent; zotarolimus

Indexed keywords

CD34 ANTIBODY; DEXAMETHASONE; EVEROLIMUS; PACLITAXEL; PIMECROLIMUS; RAPAMYCIN; TACROLIMUS; UMIROLIMUS; ZOTAROLIMUS;

BARE METAL STENT; CLINICAL EVALUATION; DRUG ELUTING STENT; FOLLOW UP; IN-STENT RESTENOSIS; MATERIAL COATING; NEOINTIMA; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; STENT THROMBOSIS; URETER OBSTRUCTION; URETER STENT; URETHRA OBSTRUCTION; URETHRAL STENT; VASCULAR PATENCY;

EID: 84907429173     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.124198     Document Type: Review

References (39)

1. Macdonald S. Carotid artery stenting trials: Conduct, results, critique, and current recommendations. Cardiovasc Intervent Radiol 2012;35:15-29.
2. Kukreja N, Onuma Y, Daemen J, Serruys PW. The future of drug-eluting stents. Pharmacol Res 2008;57:171-80.
3. Khan W, Farah S, Domb AJ. Drug eluting stents: Developments and current status. J Control Release 2012;161:703-12.
4. Alahmar AE, Grayson AD, Andron M, Egred M, Roberts ED, Patel B, et al. Reduction in mortality and target-lesion revascularization at 2 years: A comparison between drug-eluting stents and conventional bare-metal stents in the real world. Int J Cardiol 2009;132:398-404.
5. McGinty S, McKee S, Wadsworth RM, McCormick C. Modelling drug-eluting stents. Math Med Biol 2011;28:1-29.
6. Räber L, Windecker S. Current status of drug-eluting stents. Cardiovasc Ther 2011;29:176-89.
7. Martin DM, Boyle FJ. Drug-eluting stents for coronary artery disease: A review. Med Eng Phys 2011;33:148-63.
8. Waksman R, Pakala R, Baffour R, Seabron R, Hellinga D, Tio FO. Shortterm effects of biocorrodible iron stents in porcine coronary arteries. J Interv Cardiol 2008;21:15-20.
9. Moore JE Jr. Biomechanical issues in endovascular device design. J Endovasc Ther 2009;16 Suppl 1:I1-11.
10. Teomim D, Fishbien I, Golomb G, Orloff L, Mayberg M, Domb AJ. Perivascular delivery of heparin for the reduction of smooth muscle cell proliferation after endothelial injury. J Control Release 1999;60:129-42.
11. Vander Hoeven BL, Pires NM, Warda HM, Oemrawsingh PV, vanVlijmen BJ, Quax PH, et al. Drug-eluting stents: Results, promises and problems. Int J Cardiol 2005;99:9-17.
12. Burke SE, Kuntz RE, Schwartz LB. Zotarolimus (ABT-578) eluting stents. Adv Drug Deliv Rev 2006;58:437-46.
13. Matter CM, Rozenberg I, Jaschko A, Greutert H, Kurz DJ, Wnendt S, et al. Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2006;48:286-92.
14. Grube E, Buellesfeld L. Bio Matrix Biolimus A9-eluting coronary stent: A next-generation drug-eluting stent for coronary artery disease. Expert Rev Med Devices 2006;3:731-41.
15. Serruys PW, Ormiston JA, Sianos G, Sousa JE, Grube E, denHeijer P, et al. Actinomycin-eluting stent for coronary revascularization: A randomized feasibility and safety study: The ACTION trial. J Am Coll Cardiol 2004;44:1363-7.
16. Aggarwal RK, Ireland DC, Azrin MA, Ezekowitz MD, deBono DP, Gershlick AH. Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody. Circulation 1996;94:3311-7.
17. Miglionico M, Patti G, D'Ambrosio A, DiSciascio G. Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: A prospective single-center registry in high-risk patients. Catheter Cardiovasc Interv 2008;71:600-4.
18. Nakazawa G, Granada JF, Alviar CL, Tellez A, Kaluza GL, Guilhermier MY, et al. Anti-CD34 antibodies immobilized on the surface of sirolimuseluting stents enhance stent endothelialization. JACC Cardiovasc Interv 2010;3:68-75.
19. Oosterlinck W. Treatment of bulbar urethral strictures a review, with personal critical remarks. ScientificWorldJournal 2003;3:443-54.
20. Liatsikos E, Kallidonis P, Stolzenburg JU, Karnabatidis D. Ureteral stents: Past, present and future. Expert Rev Med Devices 2009;6:313-24.
21. Donnell RF. Urethral stents in benign prostate hyperplasia. Curr Urol Rep 2003;4:282-6.
22. Chapple CR, Bhargava S. Management of the failure of a permanently implanted urethral stent-A therapeutic challenge. Eur Urol 2008;54:665-70.
23. Eisenberg ML, Elliott SP, McAninch JW. Management of restenosis after urethral stent placement. J Urol 2008;179:991-5.
24. Palminteri E, Gacci M, Berdondini E, Poluzzi M, Franco G, Gentile V. Management of urethral stent failure for recurrent anterior urethral strictures. Eur Urol 2010;57:615-21.
25. Agrawal S, Brown CT, Bellamy EA, Kulkarni R. The thermo-expandable metallic ureteric stent: An 11-year follow-up. BJU Int 2009;103:372-6.
26. Liatsikos EN, Karnabatidis D, Katsanos K, Kallidonis P, Katsakiori P, Kagadis GC, et al. Ureteral metal stents: 10-year experience with malignant ureteral obstruction treatment. J Urol 2009;182:2613-7.
27. Chung SY, Stein RJ, Landsittel D, Davies BJ, Cuellar DC, Hrebinko RL, et al. 15-year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents. J Urol 2004;172:592-5.
28. Ganatra AM, Loughlin KR. The management of malignant ureteral obstruction treated with ureteral stents. J Urol 2005;174:2125-8.
29. Aravantinos E, Anagnostou T, Karatzas AD, Papakonstantinou W, Samarinas M, Melekos MD. Percutaneous nephrostomy in patients with tumors of advanced stage: Treatment dilemmas and impact on clinical course and quality of life. J Endourol 2007;21:1297-302.
30. Kallidonis P, Kitrou P, Karnabatidis D, Kyriazis I, Kalogeropoulou C, Tsamandas A, et al. Evaluation of zotarolimus-eluting metal stent in animal ureters. J Endourol 2011;25:1661-7.
31. Khandelwal P, Abraham SN, Apodaca G. Cell biology and physiology of the uroepithelium. Am J Physiol Renal Physiol 2009;297:F1477-501.
32. Kreft ME, Hudoklin S, Jezernik K, Romih R. Formation and maintenance of blood-urine barrier in urothelium. Protoplasma 2010;246:3-14.
33. Krambeck AE, Walsh RS, Denstedt JD, Preminger GM, Li J, Evans JC, et al. A novel drug eluting ureteral stent: A prospective, randomized, multicenter clinical trial to evaluate the safety and effectiveness of a ketorolac loaded ureteral stent. J Urol 2010;183:1037-42.
34. Mendez-Probst CE, Goneau LW, MacDonald KW, Nott L, Seney S, Elwood CN, et al. The use of triclosan eluting stents effectively reduces ureteral stent symptoms: A prospective randomized trial. BJU Int 2012;110:749-54.
35. Kotsar A, Nieminen R, Isotalo T, Mikkonen J, Uurto I, Kellomäki M, et al. Preclinical evaluation of new indomethacin-eluting biodegradable urethral stent. J Endourol 2012;26:387-92.
36. Shin JH, Song HY, Choi CG, Yuk SH, Kim JS, Kim YM, et al. Tissue hyperplasia: Influence of a paclitaxel-eluting covered stent-preliminary study in a canine urethral model. Radiology 2005; 234:438-44.
37. Liatsikos EN, Karnabatidis D, Kagadis GC, Rokkas K, Constantinides C, Christeas N, et al. Application of paclitaxel-eluting metal mesh stents within the pig ureter: An experimental study. Eur Urol 2007;51:217-23.
38. Tahara S, Chamié D, Baibars M, Alraies C, Costa M. Optical coherence tomography endpoints in stent clinical investigations: Strut coverage. Int J Cardiovasc Imaging 2011;27:271-87.
39. Cerri PS, Sasso-Cerri E. Staining methods applied to glycol methacrylate embedded tissue sections. Micron 2003;34:365-72.